The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MDGL's Score
Industry at a Glance
Industry Ranking
5 / 403
Overall Ranking
38 / 4582
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
16
analysts
Buy
Current Rating
415.786
Target Price
+25.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
MDGL Highlights
StrengthsRisks
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 180.13M.
Undervalued
The company’s latest PE is -44.71, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 21.99M shares, decreasing 10.45% quarter-over-quarter.